{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.0","upperLimit":"22.0","value":"14.0"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"8.0","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Time to response was defined as the time from the date of start of midostaurin treatment to the date of first response. The best overall clinical response was determined as per the clinical assessment done by the investigator. Responders were defined as all participants with a best clinical response of leukemia free state, morphological complete remission, incomplete morphological complete remission, partial remission, bone marrow blast response, bone marrow minor blast response, peripheral blood blast response, minor peripheral blood blast response. Time to response was calculated by using the formula = (date of first response -date of start of midostaurin) +1 day.","dispersionType":"Full Range","groups":[{"description":"Subjects with acute myeloid leukemia (AML) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\\^2.","id":"OG000","title":"AML Subjects"},{"description":"Subjects with mixed lineage leukemia gene- rearranged acute lymphoblastic leukemia (MLLr-ALL) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\\^2.","id":"OG001","title":"MLLr-ALL Subjects"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed in FAS population. Here, \"Number of participants analysed\" signifies number of responders at specified time points for each arm, respectively.","reportingStatus":"POSTED","timeFrame":"Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)","title":"Time to Response With Midostaurin","type":"SECONDARY","unitOfMeasure":"Days"}